Country, language and currency
- Social bookmarks:
- Testimonials
-
Read more »
Our billing is certified by:
-
- Progress report on the first sub-Saharan trial of newer versus older ... - 7thSpace Interactive (press release)
- Progress report on the first sub-Saharan trial of newer versus older
- Novartis: A Sleeper Or A Headache? - Seeking Alpha
- Novartis: A Sleeper Or A Headache?Seeking AlphaThis last quarter, Novartis missed the street estimates mainly because of looming patent expiration of some of their best-selling prescription drugs, most notably Diovan (valsartan)
- Novartis Pressures Generics Makers Over Exforge ANDA - Law360 (subscription)
- Novartis Pressures Generics Makers Over Exforge ANDALaw360 (subscription)
- Novartis expands in generics with $1.53bn Fougera buy - PMLiVE
- Novartis expands in generics with $1
- Auriga Initiates Coverage on Forest Laboratories (FRX); Lack of Near Term ... - StreetInsider.com (subscription)
- Auriga Initiates Coverage on Forest Laboratories (FRX); Lack of Near Term
